Yesterday, the President & CEO of Codexis (CDXS), John Nicols, bought shares of CDXS for $133K.
Following John Nicols’ last CDXS Buy transaction on March 23, 2018, the stock climbed by 1.8%.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.05 and a one-year low of $12.68. Currently, Codexis has an average volume of 391.27K.
Starting in September 2018, CDXS received 11 Buy ratings in a row.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics.
